COVID 19

Coronavirus disease 2019 (COVID-19) is a respiratory disease caused by infection with the SARS-CoV-2 virus, a new strain of coronavirus that was first identified during 2019-2020 pandemic

6,480,000

Delivered serology tests (June 09,2020)

Along with the spreading global pandemic of Novel Coronavirus, countries around the world have been struggling to diagnose and control this disease in time. Xiamen University and Wantai have jointly developed a series of innovative, highly sensitive and specific serological and molecular assays for testing of Covid-19. Together our tests offer total testing solution for Covid-19 diagnosis with results available in just 75-minutes. Download Wantai COVID-19 Diagnostics Test Introduction Brochure.

Wantai SARS-CoV-2 Diagnostic Kits:

SARS-CoV-2 Total Ab ELISA

SARS-CoV-2 Total Ab ELISA   Download Brochure

WANTAI SARS-CoV-2 Ab ELISA detects total antibody as indicative of an immune response to SARS-CoV-2 in patients suspected of previous SARS-CoV-2 infection, or for the detection of seroconversion in patients following known recent SARS-CoV-2 infection. The test may also be used to aid in the diagnosis of acute or past SARS-CoV-2 infection in conjunction with other tests and clinical information. The prevalence of SARS-CoV-2 infection in the area where testing has occurred should be considered when interpreting positive test results. The test should not be used as the sole basis for diagnosis.

Performance evaluations (click on the links to open each study report)

The kit detects TOTAL ANTIBODIES (IgG, IgM and IgA) against S1-RBD and it has been extensively evaluated and validated in Europe. In the Netherlands, Erasmus Medical Center showed sensitivity of 98% (100% >14days), Sanquin Blood Bank calculated PPV of 99%, 88%, and 72% in areas with prevalence of 4-10%, 2-4%, and <2% and the RIVM National Institute for Public Health reports sensitivity of 97.7% (>10 days) ~ 99.5% (>14 days) . Statens Serum Institut in Denmark showed sensitivity of 71% (7~13days) ~ 100% (10days) and the Medizinische Universität Wien in Austria calculated sensitivity of 92~100%.  In France, the French National Reference Center (CNR) evaluated the kit and conclude that it has sensitivity of 100% (7-13days), 95% (14-19days) and 98% (>20days) respectively. Over 98% agreement with automated immunoassays has been demonstrated during a study conducted by the University Hospital in Padova, Italy.  In Belgium, AZ Delta Medical Laboratories and Ghent University concluded that Wantai SARS-COV-2 Ab ELISA is suitable for sensitive and specific screening of a SARS-CoV-2 infection from 10 days after symptom onset.

Very high specificity (>98%) has been shown in all clinical studies.

FIND results are expected soon.

SARS-CoV-2 lgM ELISA

SARS-CoV-2 lgM ELISA    Download Brochure

Wantai SARS-CoV-2 lgM ELISA is an enzyme-linked immunosorbent assay for the qualitative detection of lgM-class antibodies to SARS-CoV-19 virus in human serum or plasma. It is intended for testing of patients suspected of recent infection with the SARS-CoV-2 virus. The test should not be used as the sole basis for diagnosis. The test is based on antibody-capture method.

Performance evaluations (click on the links to open each study report)

The Medizinische Universität Wien in Austria reported sensitivity of 92% (6 ~10days) to 100% after day 11 post disease onset, and 97% specificity of the kit.

FIND results are expected soon.

SARS-CoV-2 Total Ab Rapid Test

Rapid Test for Total Antibody to SARS-CoV-2 -   Click to Download Brochure

! IMPORTANT : THIS PRODUCT IS INTENDED FOR PROFESSIONAL USE ONLY, NOT FOR SELF-TESTING OR TESTING AT HOME !

WANTAI SARS-CoV-2 Ab Rapid Test is a 15minutes test that detects total antibody as indicative of an immune response to SARS-CoV-2 in patients suspected of previous SARS-CoV-2 infection, or for the detection of seroconversion in patients following known recent SARS-CoV-2 infection. The kit is based on double antigen "sandwich" method and it detects TOTAL ANTIBODIES against S1-RBD. The test may also be used to aid in the diagnosis of acute or past SARS-CoV-2 infection in conjunction with other tests and clinical information. The prevalence of SARS-CoV-2 infection in the area where testing has occurred should be considered when interpreting positive test results. The test should not be used as the sole basis for diagnosis.

Performance evaluations (click on the links to open each study report) :

In a limited validations, the RIVM National Institute for Public Health in the Netherlands, and the Ministry of Health in the Czech Republic both reported sensitivity and specificity of 100%. In Austria, the Medizinische Universität Wien calculated sensitivity of 80% (6-10days) and 100% (>11days) respectively, and the University of Innsbruck reported sensitivity of 95.7% (100% >14days) and specificity of 100%.

FIND and Doherty Institute evaluation results are expected soon.

View our how to operate video.


SARS-CoV-2 RT-PCR

SARS-CoV-2  RT-PCR

Wantai SARS-CoV-2  RT-PCR Kit is a Nucleic Acid Detection kit for the detection of Severe Acute Respiratory Syndrome Coronavirus (PCR – Fluorescence Probing).

FIND evaluation results are available here.

News Updates

Our International Distributors

2020 - Wantai BioPharm. All Rights Reserved. Designed & Developed by SweeneyVesty Studio